Medscape16d
Sliding Scale versus Tight Glycemic Control in the Noncritically Ill at a Community Hospital
Objective: To compare traditional sliding scale (SS) with a tight glycemic control ... was compared with those treated with TC (n = 210). Patients on SS insulin received a traditional SS regimen ...
optometryadvisor16d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus. HealthDay News — ...
WebMD19d
FDA OKs First Fast-Acting Insulin Biosimilar for Diabetes
Merilog, made by Sanofi-Aventis, is a rapid-acting insulin biosimilar (similar to Novo Nordisk’s Novolog) that helps control blood sugar spikes when taken five to 10 minutes before a meal.
Medical Xpress20d
FDA approves first rapid-acting insulin biosimilar for patients with diabetes
The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
healthday20d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...
Managed Healthcare Executive21d
FDA Approves First Biosimilar of Novolog
The FDA has approved Sanofi’s Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) to improve glycemic control in adults and pediatric patients with diabetes. Merilog is a ...
TiogaPublishing.com21d
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric ...
Interesting Engineering21d
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
The U.S. Food and Drug Administration (FDA) has approved Merilog, a biosimilar to the widely used insulin product Novolog (insulin aspart), to enhance glycemic control in adults and children with ...